Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 4, 2015, Pages 961-969

  Jacobson, Robert M ^a   Grill, Diane E ^a   Oberg, Ann L ^a   Tosh, Pritish K ^a   Ovsyannikova, Inna G ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aging; Antibodies; H1N1 subtype; Hemagglutination inhibition tests; Hemagglutinin glycoproteins; Influenza a virus; Influenza vaccines; Influenza virus; Viral

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL ACTIVITY; DRUG RESPONSE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLU LIKE SYNDROME; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNE RESPONSE; INFLUENZA A; INFLUENZA VACCINATION; MALE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; SEROCONVERSION; VIRUS NEUTRALIZATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; PROCEDURES;

AGED; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED;

EID: 84937627982     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1011990     Document Type: Article

References (40)

1. Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol 2001; 75:12182- 7; PMID:11711609; http://dx. doi. org/10. 1128/ JVI. 75. 24. 12182-12187. 2001
2. Bernstein E, Kaye D, Abrutyn E, Gross P, Dorfman M, Murasko DM. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999; 17:82-94; PMID:10078611; http://dx. doi. org/ 10. 1016/S0264-410X(98)00117-0
3. Nicholls S, Carroll K, Crofts J, Ben-Eliezer E, Paul J, Zambon M, Joseph CA, Verlander NQ, Goddard NL, Watson JM. Outbreak of influenza A (H3N2) in a highly-vaccinated religious community: a retrospective cohort study. Commun Dis Public Health 2004; 7:272-7; PMID:15779788
4. Engler RJ, Nelson MR, Klote MM, VanRaden MJ, Huang CY, Cox NJ, Klimov A, Keitel WA, Nichol KL, Carr WW, et al. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168:2405-14; PMID:19064822; http://dx. doi. org/ 10. 1001/archinternmed. 2008. 513
5. Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 2008; 197:490-502; PMID:18275271; http://dx. doi. org/ 10. 1086/524146
6. Bucasas KL, Franco LM, Shaw CA, Bray MS, Wells JM, Nino D, Arden N, Quarles JM, Couch RB, Belmont JW. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011; 203:921-9; PMID:21357945; http://dx. doi. org/10. 1093/infdis/ jiq156
7. Henn AD, Wu S, Qiu X, Ruda M, Stover M, Yang H, Liu Z, Welle SL, Holden-Wiltse J, Wu H, et al. Highresolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature. Sci Rep 2013; 3:2327; PMID:23900141; http://dx. doi. org/10. 1038/srep02327
8. Furman D, Jojic V, Kidd B, Shen-Orr S, Price J, Jarrell J, Tse T, Huang H, Lund P, Maecker HT, et al. Apoptosis and other immune biomarkers predict influenza vaccine responsiveness (vol 9, pg 659, 2013). Mol Syst Biol 2013; 9; 659; PMID:23591775; http://dx. doi. org/10. 1038/ msb. 2013. 15
9. Center for Biologics Evaluation and Research, Food and Drug Administration, U. S. Department of Health and Human Services. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. In: Food and Drug Administration, ed. Guidelines for Industry. Rockville, MD: Food and Drug Administration; 2007:PDF.
10. Center for Biologics Evaluation and Research, Food and Drug Administration, U. S. Department of Health and Human Services. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. In: Food and Drug Administration, ed. Guidelines for Industry. Rockville, MD: Food and Drug Administration; 2007:PDF.
11. Reber A, Katz J. Immunological assessment of influenza vaccines and immune correlates of protection. Expert Rev Vaccines 2013; 12:519-36; PMID:23659300; http://dx. doi. org/10. 1586/erv. 13. 35
12. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu XH, Lim W, Fukuda K, Cox NJ, Katz JM. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43; PMID:10074505
13. Painter SD, Haralambieva IH, Ovsyannikova IG, Grill DE, Poland GA. Detection of influenza A/ H1N1-specific human IgG-secreting B cells in older adults by ELISPOT assay. Viral Immunol 2014; 27:32-8; PMID:24605786; http://dx. doi. org/ 10. 1089/vim. 2013. 0099
14. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22; PMID:15087226; http://dx. doi. org/10. 1016/j. jim. 2003. 12. 015
15. Khurana S, Frasca D, Blomberg B, Golding H. AID Activity in B Cells Strongly Correlates with Polyclonal Antibody Affinity Maturation in-vivo Following Pandemic 2009-H1N1 Vaccination in Humans. Plos Pathog 2012; 8; e1002920; PMID:23028320; http:// dx. doi. org/10. 1371/journal. ppat. 1002920
16. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine Failures. J Infect Dis 2011; 203:1309-15; PMID:21378375; http://dx. doi. org/10. 1093/infdis/jir015
17. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. J Infect Dis 2011; 204:1879-85; PMID:21998477; http://dx. doi. org/10. 1093/infdis/jir661
18. Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J Hyg (Lond) 1972; 70:767-77; PMID:4509641; http://dx. doi. org/10. 1017/ S0022172400022610
19. Ndifon W, Dushoff J, Levin SA. On the use of hemagglutination- inhibition for influenza surveillance: Surveillance data are predictive of influenza vaccine effectiveness. Vaccine 2009; 27:2447-52; PMID:19368786; http://dx. doi. org/10. 1016/j. vaccine. 2009. 02. 047
20. Ng S, Fang VJ, Ip DKM, Chan KH, Leung GM, Peiris JSM, Cowling BJ. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis 2013; 208:1320-4; PMID:23908481; http://dx. doi. org/10. 1093/infdis/jit372
21. Gorse GJ, O'Connor TZ, Newman FK, Mandava MD, Mendelman PM, Wittes J, Peduzzi PN. Immunity to influenza in older adults with chronic obstructive pulmonary disease. J Infect Dis 2004; 190:11-9; PMID:15195238; http://dx. doi. org/10. 1086/421121
22. Webster RG, Kasel JA, Couch RB, Laver WG. Influenza- Virus Subunit Vaccines . 2. Immunogenicity and Original Antigenic Sin in Humans. J Infect Dis 1976; 134:48-58; PMID:59787; http://dx. doi. org/10. 1093/ infdis/134. 1. 48
23. Selin LK, Lin MY, Kraemer KA, Pardoll DM, Schneck JP, Varga SM, Santolucito PA, Pinto AK, Welsh RM. Attrition of T cell memory: Selective loss of LCMV epitope-specific memory CD8 T cells following infections with heterologous viruses. Immunity 1999; 11:733-42; PMID:10626895; http://dx. doi. org/ 10. 1016/S1074-7613(00)80147-8
24. Welsh RM, Selin LK. No one is naive: The significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2:417-26; PMID:12093008
25. Chen HD, Fraire AE, Joris I, Welsh RM, Selin LK. Specific history of heterologous virus infections determines anti-viral immunity and immunopathology in the lung. Am J Pathol 2003; 163:1341-55; PMID:14507643; http://dx. doi. org/10. 1016/S0002- 9440(10)63493-1
26. Salk JE, Pearson HE, et al. Immunization against influenza with observations during an epidemic of influenza A one year after vaccination. Am J Hyg 1945; 42:307- 22; PMID:21005133
27. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009; 361:1260-7; PMID:19776407; http://dx. doi. org/10. 1056/ NEJMoa0808652
28. Ovsyannikova IG, White SJ, Albrecht RA, Garcia- Sastre A, Poland GA. Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/ H1N1. Viral Immunology 2014; 27:174-8; PMID:24787023; http://dx. doi. org/10. 1089/ vim. 2013. 0111
29. Ovsyannikova IG, White SJ, Larrabee BR, Grill DE, Jacobson RM, Poland GA. Leptin and leptinrelated gene polymorphisms, obesity, and influenza A/H1N1 vaccine-induced immune responses in older individuals. Vaccine 2014; 32:881-7; PMID:24360890; http://dx. doi. org/10. 1016/j. vaccine. 2013. 12. 009
30. U. S. Food and Drug Administration. Influenza Virus Vaccine for the 2010-2011 Season. Silver Spring, MD 2014.
31. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31:103-15; PMID:1100130; http://dx. doi. org/10. 2307/2529712
32. Burnet FM, Stone JD. The receptor-destroying enzyme of V. cholera. Austr J Exper Med Sci 1947; 25:227-33; PMID:20270643; http://dx. doi. org/10. 1038/ icb. 1947. 33
33. Robinson RQ, Dowdle WR. Influenza viruses. In: Lennette EH, Schmidt NJ, eds. Diagnostic Procedures for Viral and Rickettsial Diseases. New York: American Public Health Association; 1969:414-33.
34. Wang S, Taaffe J, Parker C, Solorzano A, Cao H, Garcia- Sastre A, Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codonoptimized HA DNA vaccines. J Virol 2006; 80:11628- 37; PMID:16987975; http://dx. doi. org/10. 1128/ JVI. 01065-06
35. WHO Global Influenza Surveillance Network, World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza. Geneva: World Health Organization; 2011.
36. Cottey R, Rowe CA, Bender BS. Unit 19:11 Influenza Virus. Curr Protoc Immunol 2001; 42(19. 11):19. 11. 1-32. PMID:18432752
37. Bentebibel SE, Lopez S, Obermoser G, Schmitt N, Mueller C, Harrod C, Flano E, Mejias A, Albrecht RA, Blankenship D, et al. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5:176ra32; PMID:23486778; http://dx. doi. org/10. 1126/scitranslmed. 3005191
38. Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, et al. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine 2009; 27:5091-5; PMID:19577636; http://dx. doi. org/10. 1016/j. vaccine. 2009. 06. 057
39. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, et al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 2011; 470:543-U136; PMID:21350488; http://dx. doi. org/10. 1038/nature09737
40. Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, He F, Noah DL, Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis 2008; 198:1309-16; PMID:18808338; http://dx. doi. org/10. 1086/592172